- Home
- CPT vs ASND Comparison
CPT vs ASND Comparison
Compare CPT & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPT | ASND |
|---|---|---|
| Founded | 1993 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 12.2B |
| IPO Year | 1993 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CPT | ASND |
|---|---|---|
| Price | $104.40 | $205.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 15 |
| Target Price | $119.78 | ★ $256.27 |
| AVG Volume (30 Days) | ★ 1.5M | 640.2K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | ★ 4.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $1,578,428,000.00 | $758,592,045.00 |
| Revenue This Year | $2.48 | $99.74 |
| Revenue Next Year | $1.94 | $79.40 |
| P/E Ratio | $42.02 | ★ N/A |
| Revenue Growth | 1.41 | ★ 97.46 |
| 52 Week Low | $97.17 | $118.03 |
| 52 Week High | $126.55 | $223.19 |
Technical Indicators
Market Signals| Indicator | CPT | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 49.09 | 49.03 |
| Support Level | $105.68 | $198.30 |
| Resistance Level | $106.77 | $218.50 |
| Average True Range (ATR) | 1.51 | 9.16 |
| MACD | 0.07 | -0.64 |
| Stochastic Oscillator | 43.34 | 28.05 |
Price Performance
Historical ComparisonAbout CPT Camden Property Trust
Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 177 multifamily properties comprised of nearly 59,996 apartment homes across the United States.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.